PROCEPT BioRobotics Corporation

Stage 4 · Declining · week 17

As of Oct 22, 2026, PROCEPT BioRobotics is in Stage 4, the downtrend phase, now in week 17 (since Jun 30, 2026). It closed at $20.03, 45.8% below its 52-week high and below its 200-day average, which is falling.

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. More about the company

$20.03

+9.63% today

$1.1B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is PRCT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 14w

S2 34w

S2 21w

S4 15w

S4 42w

S4 16w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 1w → S4 14w → S1 3w → S2 34w → S3 2w → S2 21w → S3 5w → S4 15w → S1 8w → S4 42w → S1 4w → S4 16w current

Total tracked: 165 weeks across 12 stage runs.

PRCT among Medical Devices82nd of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…82	PRCTPROCEPT BioRobotics Corporation	Stage 4 · wk 17	27	+10.7%

vs 52W High

-45.8%

$16.69 lo$36.95 hi

45.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 17

1w13w26w

Week 17, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-15.5%

200 DMA: $23.70 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.98x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+10.7%

+20.0%

-17.4%

YTD

-34.9%

-42.1%

Scan Membership

Breakout Watch

Latest: 2024-08-28

4 appearances in last 60 days. First seen: 2022-06-30.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 17 · Vol 0.98x

2026-10-21S4

Wk 16 · Vol 0.46x

2026-10-20S4

Wk 16 · Vol 0.79x

2026-10-19S4

Wk 16 · Vol 0.80x

2026-10-16S4

Wk 16 · Vol 0.93x

2026-10-15S4

Wk 16 · Vol 0.91x

2026-10-14S4

Wk 15 · Vol 1.22x

2026-10-13S4

Wk 15 · Vol 1.27x

2026-10-12S4

Wk 15 · Vol 1.45x

2026-10-09S4

Wk 15 · Vol 0.79x

2026-10-08S4

Wk 15 · Vol 0.84x

2026-10-07S4

Wk 14 · Vol 0.81x

Moving averages & range

50 DMA

$19.59

200 DMA

$23.70

52W High

$36.95

52W Low

$16.69

5D Low

$17.57

Resistance levels (recent highs)

20d High

$20.03

60d High

$22.89

120d High

$29.09

250d High

$36.95

Next resistance

+14.3%

to 60d High

ROE

-30.2%

Profit margin -32.5%

Dividend Yield

0.00%

P/B 3.4

PROCEPT BioRobotics: quick answers

What stage is PROCEPT BioRobotics in?

As of Oct 22, 2026, PROCEPT BioRobotics (PRCT) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 30, 2026 and is in week 17. What the four stages mean

Is PROCEPT BioRobotics in an uptrend?

No. PROCEPT BioRobotics is in a Stage 4 downtrend. It trades 15.5% below its 200-day average, which is falling.

How far is PROCEPT BioRobotics from its 52-week high?

PROCEPT BioRobotics closed at $20.03 on Oct 22, 2026, 45.8% below its 52-week high of $36.95. Its 52-week low is $16.69.

How has PROCEPT BioRobotics performed over the past year?

As of Oct 22, 2026, PROCEPT BioRobotics is down 42.1% over the past year and down 34.9% so far in 2026.

Which sector and industry is PROCEPT BioRobotics in?

PROCEPT BioRobotics is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.